#151376

Anti-CD79b [B29/123] mAb

Cat. #151376

Anti-CD79b [B29/123] mAb

Cat. #: 151376

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: CD79b

Class: Monoclonal

Application: IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jacqueline Cordell

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CD79b [B29/123] mAb
  • Alternate name: CD79b Molecule; CD79B Antigen (Immunoglobulin-Associated Beta); Immunoglobulin-Associated B29 Protein; B-Cell-Specific Glycoprotein B29; Ig-Beta
  • Clone: B29/123
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; WB
  • Description: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling.
  • Immunogen: Synthetic peptide representing the c-terminus from residue 215 of the murine B29 polypeptide.
  • Isotype: IgG2b
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: CD79b
  • Target background: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling.

Applications

  • Application: IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Hauser et al. 2013. Mol Immunol. 54(3-4):247-53. PMID: 23318223.
  • Broad feedback inhibition of pre-B-cell receptor signaling components.
  • Ouchida et al. 2010. J Immunol. 185(1):294-301. PMID: 20519653.
  • A role for lysosomal-associated protein transmembrane 5 in the negative regulation of surface B cell receptor levels and B cell activation.
  • Lankester et al. 1994. J Immunol. 152(5):2157-62. PMID: 8133032.
  • Evidence for a direct physical interaction of membrane IgM, IgD, and IgG with the B29 gene product.
  • Jones et al. 1993. J Immunol. 150(12):5429-35. PMID: 8515069.
  • Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies.
  • Brouns et al. 1993. Eur J Immunol. 23(5):1088-97. PMID: 8477803.
  • The structure of the mu/pseudo light chain complex on human pre-B cells is consistent with a function in signal transduction.
  • Mason et al. 1992. Eur J Immunol. 22(10):2753-6. PMID: 1396979.
  • The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation.